Sangamo Therapeutics, Inc.

Good afternoon, and welcome to the Sangamo Therapeutics fourth quarter and full year 2025 teleconference call. Please be advised that today's conference is being recorded. I would now like to turn the conference over to your speaker today, Louise Wilkie, Head of Investor Relations and Corporate Communications. Please go ahead.

Thank you. Good afternoon, everyone. Thank you for joining us on the call today. On this call are several members of the Sangamo Executive Leadership Team, including Sandy McRae, Chief Executive Officer, Natalie Dubois-Stringfellow, Chief Development Officer, Nikunj Jain, Interim Chief Financial Officer, and Greg Davis, Head of Research and Technology. Slides from our corporate presentation can be found on our website, sangamo.com, and under the Presentations page of the Investors and Media section. This call includes forward-looking statements regarding Sangamo's current expectations. These statements include, but are not limited to, Statements related to Sangamo's cash runway, Sangamo's plans to obtain additional capital and its ability to continue to operate as a going concern, the therapeutic and commercial potential and value of Sangamo's product candidates and technologies, Sangamo's ability to establish and maintain collaborations and strategic partnerships, including for its fibroid disease programme, the anticipated plans of Sangamo and its collaborators for clinical trials, regulatory submissions and regulatory approvals, and other statements that are not historical fact. Actual results may differ materially from what we discussed today. These statements are subject to certain risks and uncertainties as are discussed in our filings of the SEC, specifically in our annual report on Form 10K for the fiscal year ended December 31, 2025, and subsequent filings and reports that Sangoma makes from time to time with the SEC. The forward-looking statements today are, the forward-looking statements stated today are made as of today, and we undertake no duty to update such information except as required by law. Please note that all forward-looking statements about our future plans and expectations are subject to our ability to secure adequate additional funding. Now, I'll turn the call over to our CEO, Sandy McRae.

Thank you, Louise, and good afternoon to everyone joining the call today. Sangam will continue to make significant pipeline progress in 2025 and into the first quarter of 26. Set against a backdrop of regulatory and market uncertainty and with limited cash resources, In June, we announced positive top-line results from the Registrational STAR study in Fabry disease, including a positive mean annualized estimated glomerular filtration rate, or EGFR, slope at 52 weeks across all dose patients in the study, which, as the US FDA reiterated in October 2025, may serve as the primary basis of approval under an accelerated approval pathway. The rolling submission of a biologics license agreement, or BLA, to the FDA is in progress, seeking ST920 approval, Sangamo's first ever wholly owned BLA submission. We transitioned to become a clinical stage neurology company with six clinical sites activated in the Phase 1-2 STAMP study in chronic neuropathic pain. In April, we continue to demonstrate that we're a collaborator of choice for neurotropic capsids with the announcements of a third neurology capsid license agreement, this time with Eli Lilly, to deliver genomic medicines for up to five central nervous system disease targets. And we have raised over $130 million in funding since the start of 2025 through non-dilutive license fees and milestone payments, as well as equity financing. These are important achievements, and I would like to sincerely thank everyone at Saigon for their hard work, dedication, and continued focus on our mission to help patients in need. I would now like to hand directly over to Natalie Dubois-Stringfell, our Chief Development Officer, to provide recent business updates from our prioritised pipeline. I will then close the call by summarising the key broader business takeaways from this quarter. Natalie.